Collaboration utilizes Artiva’s proprietary off-the-shelf allogeneic NK cell and CAR technology platforms to develop up to three CAR-NK cell therapies targeting solid tumor-associated antigens Artiva to receive $30 million upfront payment and up to $612 million per program in potential future development and commercial milestones, and royalties on any future worldwide product sales Artiva to…
SAN DIEGO, January 5, 2021 — Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, announced today the appointment of Fred Aslan, M.D., as President and Chief Executive Officer. Dr. Aslan brings a twenty-year track record as an executive and investor in the…